ArticleMethods in molecular biology (Clifton, N.J.)2015
Mouse models of breast cancer.
Article in Methods in molecular biology (Clifton, N.J.), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Development of immunocompetent models for primary and metastatic ER+ breast cancer.Animal models and experimental medicine · 2026Article
- Necroptosis in both tumour and stromal compartments determines responsiveness to immunogenic cell death-based immunotherapy.Nature communications · 2026Article
- Transcriptomic profiling of PBMCs from mammary tumor dogs reveals two distinct immune states.American journal of cancer research · 2025Article
- Mechanism of isoflurane‑mediated breast cancer growthOncology letters · 2024Article
- Isolating Primary Tumor Cells from the MMTV-PyMT Mouse Model and Their Use in Developing an Orthotopic Mouse Model of Breast Cancer.Methods in molecular biology (Clifton, N.J.) · 2024Article
- Review
- Integrative multi-omic sequencing reveals the MMTV-Myc mouse model mimics human breast cancer heterogeneity.Breast cancer research : BCR · 2023Article
- Gestational Breast Cancer - a Review of Outcomes, Pathophysiology, and Model Systems.Journal of mammary gland biology and neoplasia · 2023Review
- Ecdysoneless Overexpression Drives Mammary Tumorigenesis through Upregulation of C-MYC and Glucose Metabolism.Molecular cancer research : MCR · 2022Article
- Identification of early biomarkers in saliva in genetically engineered mouse model C(3)1-TAg of breast cancer.Scientific reports · 2022Article
- Article
- Article
- Dual recombinase action in the normal and neoplastic mammary gland epithelium.Scientific reports · 2021Article
- C(3)1-TAg in C57BL/6 J background as a model to study mammary tumor development.Histochemistry and cell biology · 2021Article
- Postponing tumor onset and tumor progression can be achieved by alteration of local tumor immunity.Cancer cell international · 2021Article
- Engineering Breast Cancer On-chip-Moving Toward Subtype Specific Models.Frontiers in bioengineering and biotechnology · 2021Review
- Biomimetic Microfluidic Platforms for the Assessment of Breast Cancer Metastasis.Frontiers in bioengineering and biotechnology · 2021Review
- Mammary Cancer Models: An Overview from the Past to the Future.In vivo (Athens, Greece)Review
- Combined Ultrasound Treatment with Transferrin-Coupled Nanoparticles Improves Active Targeting of 4T1 Mammary Carcinoma Cells.Technology in cancer research & treatmentArticle
- Emerging roles of DYRK2 in cancer.The Journal of biological chemistryReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Breast cancer is the most common cause of cancer death in women worldwide. This malignancy is a complex disease, which is defined by an intrinsic heterogeneity on the histopathological and molecular level as well as response to therapy and outcome. In addition to classical histopathological features, breast cancer can be categorized into at least five major subtypes based on comprehensive gene expression profiling: luminal A, luminal B, basal-like, ERBB2-positive, and normal-like breast cancer. Genetically engineered mouse models can serve as tools to study the molecular underpinnings for this disease. Given the genetic complexity that drives the initiation and progression of individual breast cancer subtypes, it is evident that certain models can reflect only particular aspects of this malignancy. In this book chapter, we will primarily focus on advances in modeling breast cancer at defined stages of carcinogenesis using genetically engineered mice. We will discuss the ability as well as shortcomings of these models to faithfully recapitulate the spectrum of human breast cancer subtypes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.